Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-03 22:03 | 2026-06-02 | OTLK | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | Biological Products, (No Diagnostic Substances) | BUY | $0.83 | 29,000 | $24,145 | 66,167 | +78.0% |
| 2026-06-03 21:36 | 2026-06-02 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Officer; Chief Business Officer | Pharmaceutical Preparations | BUY | $7.50 | 13,500 | $101,219 | 75,300 | +21.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Officer; CFO & Chief Business Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.97 | 19,360 | $38,221 | 379,900 | -4.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Officer; Principal Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.94 | 9,184 | $17,813 | 95,461 | -8.8% |
| 2026-06-03 21:30 | 2026-06-02 | ALEC | Alector, Inc. | Rosenthal Arnon | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | SALE | $1.97 | 87,216 | $172,191 | 2,367,206 | -3.6% |
| 2026-06-03 21:33 | 2026-06-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer; CHIEF MEDICAL OFFICER | Pharmaceutical Preparations | SALE | $30.58 | 1,795 | $54,891 | 34,826 | -4.9% |
| 2026-06-03 21:34 | 2026-06-01 | IONS | IONIS PHARMACEUTICALS INC | BERTHELSEN SPENCER R | Director | Pharmaceutical Preparations | OPT+S | $75.67 | 8,000 | $605,360 | 156,013 | -4.9% |
| 2026-06-03 21:09 | 2026-06-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | Pharmaceutical Preparations | SALE | $235.12 | 6,000 | $1,410,720 | 372,682 | -1.6% |
| 2026-06-03 21:01 | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer; President, R&D & CMO | Biological Products, (No Diagnostic Substances) | OPT+S | $25.66 | 14,853 | $381,112 | 0 | -100.0% |
| 2026-06-03 21:04 | 2026-06-01 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | Director, Officer; Chief Executive Officer | Biological Products, (No Diagnostic Substances) | SALE | $26.20 | 6,643 | $174,048 | 27,970 | -19.2% |
| 2026-06-03 20:34 | 2026-06-02 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $538.39 | 9,500 | $5,114,742 | 40,513 | -19.0% |
| 2026-06-03 16:41 | 2026-06-02 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | Pharmaceutical Preparations | BUY | $9.43 | 50,000 | $471,300 | 886,000 | +6.0% |
| 2026-06-02 20:12 | 2026-05-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer; CSBO | Biological Products, (No Diagnostic Substances) | OPT+S | $26.34 | 7,500 | $197,554 | 24,808 | -23.2% |
| 2026-06-02 20:05 | 2026-06-01 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Director, Officer; President & CEO | Biological Products, (No Diagnostic Substances) | SALE | $19.44 | 5,466 | $106,253 | 594,538 | -0.9% |
| 2026-06-02 20:25 | 2026-06-02 | ASND | Ascendis Pharma A/S | SMITH SCOTT THOMAS | Officer; EVP & Chief Financial Officer | Pharmaceutical Preparations | BUY | $219.00 | 100 | $21,900 | 4,367 | +2.3% |
| 2026-06-02 20:05 | 2026-05-29 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $69.75 | 14,205 | $990,799 | 120,094 | -10.6% |
| 2026-06-02 20:05 | 2026-05-29 | TWST | Twist Bioscience Corp | Laponis Adam | Officer; Chief Financial Officer | Biological Products, (No Diagnostic Substances) | SALE | $70.00 | 4,000 | $280,000 | 112,675 | -3.4% |
| 2026-06-02 20:30 | 2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer; Chief Financial Officer | Pharmaceutical Preparations | SALE | $18.99 | 1,177 | $22,351 | 139,252 | -0.8% |
| 2026-06-02 20:30 | 2026-06-01 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $18.99 | 6,847 | $130,025 | 484,843 | -1.4% |
| 2026-06-02 20:05 | 2026-06-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | Biological Products, (No Diagnostic Substances) | OPT+S | $9.62 | 9,747 | $93,766 | 130,079 | -7.0% |
| 2026-06-02 20:05 | 2026-06-01 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer; Chief Executive Officer | Pharmaceutical Preparations | SALE | $69.74 | 12,837 | $895,252 | 2,565,489 | -0.5% |
| 2026-06-03 01:54 | 2026-05-29 | AUPH | Aurinia Pharmaceuticals Inc. | TANG KEVIN | Director, Officer, 10% owner; Chief Executive Officer | Pharmaceutical Preparations | BUY | $15.29 | 814,606 | $12,455,244 | 13,044,106 | +6.7% |
| 2026-06-03 00:35 | 2026-06-01 | GNLX | GENELUX Corp | Thomas John | Director | Pharmaceutical Preparations | SALE | $2.98 | 10,000 | $29,801 | 472,784 | -2.1% |
| 2026-06-03 00:34 | 2026-05-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner; CEO and Chairman | Pharmaceutical Preparations | SALE | $4.72 | 652 | $3,075 | 181,509 | -0.4% |
| 2026-06-02 23:50 | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | Pharmaceutical Preparations | OPT+S | $100.00 | 3,977 | $397,700 | 0 | -100.0% |
| 2026-06-02 23:50 | 2026-06-01 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer; CHIEF EXECUTIVE OFFICER | Pharmaceutical Preparations | OPT+S | $95.84 | 30,000 | $2,875,104 | 194,309 | -13.4% |
| 2026-06-02 23:14 | 2026-06-02 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer; Chief Legal Officer | Pharmaceutical Preparations | OPT+S | $16.60 | 8,148 | $135,253 | 13,579 | -37.5% |
| 2026-06-02 22:56 | 2026-05-29 | PAHC | PHIBRO ANIMAL HEALTH CORP | CORCORAN E THOMAS | Director | Pharmaceutical Preparations | BUY | $31.77 | 10,000 | $317,700 | 41,459 | +31.8% |
| 2026-06-02 23:00 | 2026-05-29 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Director | Pharmaceutical Preparations | SALE | $229.20 | 17,537 | $4,019,470 | 29,603 | -37.2% |
| 2026-06-02 23:00 | 2026-06-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Randhawa Simrat | Officer; EVP, Head of R&D | Pharmaceutical Preparations | OPT+S | $90.62 | 26,530 | $2,404,077 | 4,000 | -86.9% |
| 2026-06-02 22:46 | 2026-06-01 | NBP | NovaBridge Biosciences | Xu Cong Claire | Officer; SVP, Clinical Development | Pharmaceutical Preparations | OPT+S | $3.94 | 3,494 | $13,766 | 290,154 | -1.2% |
| 2026-06-02 22:22 | 2026-06-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | Officer; CLO & Secretary | Pharmaceutical Preparations | OPT+S | $227.06 | 5,000 | $1,135,316 | 41,382 | -10.8% |
| 2026-06-02 22:05 | 2026-06-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer; See Remarks | Pharmaceutical Preparations | SALE | $6.06 | 16,667 | $100,982 | 1,176,506 | -1.4% |
| 2026-06-02 22:08 | 2026-06-01 | NBIX | NEUROCRINE BIOSCIENCES INC | Onyia Jude | Officer; Chief Scientific Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $160.25 | 11,000 | $1,762,710 | 25,846 | -29.9% |
| 2026-06-02 22:18 | 2026-06-01 | HYPD | HYPERION DEFI, INC. | Jung Hyunsu | Director, Officer; See Remarks | Pharmaceutical Preparations | BUY | $3.70 | 8,000 | $29,580 | 1,385,676 | +0.6% |
| 2026-06-02 22:03 | 2026-05-29 | NBIX | NEUROCRINE BIOSCIENCES INC | Delaet Ingrid | Officer; Chief Regulatory Officer | Biological Products, (No Diagnostic Substances) | OPT+S | $156.71 | 2,261 | $354,321 | 16,225 | -12.2% |
| 2026-06-02 22:04 | 2026-06-01 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer; Chairman & CEO | Biological Products, (No Diagnostic Substances) | SALE | $131.46 | 15,000 | $1,971,846 | 617,567 | -2.4% |
| 2026-06-02 21:35 | 2026-06-01 | VIR | Vir Biotechnology, Inc. | Napolitano Janet | Director | Biological Products, (No Diagnostic Substances) | SALE | $9.45 | 3,200 | $30,240 | 21,216 | -13.1% |
| 2026-06-02 21:20 | 2026-06-01 | HALO | HALOZYME THERAPEUTICS, INC. | Connaughton Bernadette | Director | Biological Products, (No Diagnostic Substances) | SALE | $66.21 | 1,625 | $107,591 | 43,669 | -3.6% |
| 2026-06-02 21:31 | 2026-06-01 | VIR | Vir Biotechnology, Inc. | Sabatini Brent | Officer; SVP, Chief Accounting Officer | Biological Products, (No Diagnostic Substances) | SALE | $9.45 | 379 | $3,582 | 61,902 | -0.6% |
| 2026-06-02 20:48 | 2026-06-01 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer; See Remarks | Biological Products, (No Diagnostic Substances) | SALE | $10.02 | 1,922 | $19,258 | 1,057,231 | -0.2% |
| 2026-06-02 20:30 | 2026-05-29 | CNTB | Connect Biopharma Holdings Ltd | Huang James | Director | Pharmaceutical Preparations | BUY | $2.48 | 150,000 | $371,610 | 13,310,000 | +1.1% |
| 2026-06-02 20:31 | 2026-05-29 | ANTX | AN2 Therapeutics, Inc. | Williams Sarah Joanne | Officer; Principal Accounting Officer | Pharmaceutical Preparations | SALE | $4.43 | 265 | $1,174 | 66,583 | -0.4% |
| 2026-06-02 20:32 | 2026-05-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | SALE | $575.96 | 1,500 | $863,947 | 43,153 | -3.4% |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer; CFO AND TREASURER | Pharmaceutical Preparations | OPT+S | $547.87 | 10,000 | $5,478,663 | 18,876 | -34.6% |
| 2026-06-02 20:33 | 2026-06-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Pharmaceutical Preparations | OPT+S | $547.91 | 9,500 | $5,205,104 | 40,513 | -19.0% |
| 2026-06-02 20:04 | 2026-05-29 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer; EVP and CMO | Pharmaceutical Preparations | SALE | $450.00 | 1,974 | $888,300 | 22,760 | -8.0% |
| 2026-06-02 13:00 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Gryaznov Sergei | Officer; Chief Scientific Officer | Pharmaceutical Preparations | BUY | $1.35 | 2,000 | $2,690 | 46,511 | +4.5% |
| 2026-06-02 13:01 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | Pharmaceutical Preparations | BUY | $1.34 | 75,000 | $100,200 | 1,519,178 | +5.2% |
| 2026-06-02 13:02 | 2026-06-01 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner; Chief Executive Officer | Pharmaceutical Preparations | BUY | $1.39 | 72,700 | $100,886 | 976,121 | +8.0% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.